Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 4Pancreatic Neoplasms 2Digestive System Neoplasms 2Pancreatic cancer, adult 1Pancreatic Diseases 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Multiple Myeloma 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Endocrine Gland Neoplasms 1Digestive System Diseases 1Colorectal Neoplasms 1Carcinoma, Pancreatic Ductal 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Adenoma, Islet Cell 1Adenocarcinoma 1

Interventions

Nivolumab 3osimertinib 2Pemetrexed 2Cetuximab 2Carboplatin 2spartalizumab 1napabucasin 1guadecitabine 1gallium 68 PSMA-11 1ficlatuzumab 1exemestane 1entinostat 1dostarlimab 1darolutamide 1apalutamide 1abexinostat 1Tyrosine Kinase Inhibitors 1Ramucirumab 1Radiosurgery 1Paclitaxel 1Leucovorin 1Irinotecan 1Interleukin-2 1Indocyanine Green 1HuMax-IL8 1Granulocyte-Macrophage Colony-Stimulating Factor 1Gemcitabine 1Fulvestrant 1Fluorouracil 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms by Site × napabucasin × Clear all
NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡